A review of venous thromboembolism in COVID‐19: A clinical perspective

Coronavirus disease‐19 (COVID‐19) started in Wuhan, China in December 2019 and spread to all around the world in a short period of time. Hospitalized patients with COVID‐19 mostly could suffer from an abnormal coagulation activation risk with increased venous thrombosis events and a poor clinical co...

Full description

Saved in:
Bibliographic Details
Published in:The Clinical Respiratory Journal 2021-05, Vol.15 (5), p.506-512
Main Authors: Ozsu, Savas, Gunay, Ersin, Konstantinides, Stavros V.
Format: Article
Language:English
Subjects:
anticoagulation
COVID-19
COVID-19 - complications
COVID-19 - epidemiology
Critical Illness
Global Health
Hospitalization
Humans
Incidence
LMWH
mortality
Original
Pandemics
SARS-CoV-2
Thromboembolism
Venous Thromboembolism - epidemiology
Venous Thromboembolism - etiology
venous thrombosis
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Coronavirus disease‐19 (COVID‐19) started in Wuhan, China in December 2019 and spread to all around the world in a short period of time. Hospitalized patients with COVID‐19 mostly could suffer from an abnormal coagulation activation risk with increased venous thrombosis events and a poor clinical course. The reported incidence rates of thrombotic complications in hospitalized COVID‐19 patients vary between 2.6 and 85% (both in non‐critically ill and critically ill patients). The risk of venous thromboembolism is not known in non‐hospitalized patients with COVID‐19. There are numerous studies and guidelines for administration of thromboprophylaxis for COVID‐19 cases. All hospitalized COVID‐19 patients should take pharmacological thromboprophylaxis if there is no contraindication. However, there is no consensus on this issue. In this review, we discussed all these approaches in a critical perspective.
ISSN:1752-6981
1752-699X
DOI:10.1111/crj.13330